HACD3: A Potential Drug Target and Biomarker (G51495)

Target Name: HACD3

NCBI ID: G51495

HACD3

HACD3: A Potential Drug Target and Biomarker

Hydroxyacyl-[acyl-carrier protein] dehydratase 3 (HACD3) is a enzyme involved in the synthesis of very-long-chain (3R) fatty acids, which are a type of fatty acid found in many organisms. HACD3 is the third gene in the human proteome to be identified that encodes an enzyme involved in the synthesis of very-long-chain (3R) fatty acids. HACD3 is a key enzyme in the synthesis of 3-hydroxyacyl-[acyl-carrier protein] (3-HACP), which is a key intermediate step in the synthesis of 3-hydroxyacyl-[acyl-carrier protein] dehydratase (3-HACSD), a crucial enzyme in the synthesis of very-long-chain (3R) fatty acids.

HACD3 is a protein that is expressed in a variety of tissues and cells in the human body, including muscle, heart, and brain. HACD3 is involved in the synthesis of very-long-chain (3R) fatty acids, which are an essential component of many biological processes. The production of 3-HACP from HACD3 is a critical step in the synthesis of 3-HACSD, which is then converted to 3-HACSD-CoA, the starting material for the synthesis of fatty acids.

HACD3 is a potential drug target because of its involvement in the synthesis of 3-HACSD, which has been shown to play a role in a variety of diseases, including obesity, type 2 diabetes, and cardiovascular disease. In addition, HACD3 has also been shown to be involved in the regulation of inflammation, which is a major risk factor for a variety of diseases.

HACD3 is also a potential biomarker for the diagnosis and monitoring of various diseases. For example, HACD3 has been shown to be involved in the regulation of muscle mass and function, which is an important predictor of overall health and quality of life. In addition, HACD3 has also been shown to be involved in the regulation of insulin sensitivity, which is a key factor in the development of type 2 diabetes.

In conclusion, HACD3 is a protein that is involved in the synthesis of very-long-chain (3R) fatty acids and has been shown to play a role in a variety of biological processes. HACD3 is a potential drug target and biomarker for a variety of diseases, including obesity, type 2 diabetes, and cardiovascular disease. Further research is needed to fully understand the role of HACD3 in these diseases and to develop effective treatments.

Protein Name: 3-hydroxyacyl-CoA Dehydratase 3

Functions: Catalyzes the third of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of fatty acid elongation. Thereby, it participates in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. May be involved in Rac1-signaling pathways leading to the modulation of gene expression. Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571)

The "HACD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HACD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets